Summary
No substantive evaluation against FDA-approved labeling is possible because the provided text does not correspond to the AI-generated response for the specific FDA label product (VYKOURA) and the supplied “label assessment” content itself states it cannot map claims to label language without the exact medical claim. Therefore, alignment cannot be established and potential misalignment risk is high.
Category Scores
Accurate Statements
Unsupported Statements
Leucovorin is used to reduce or “rescue” the effects of certain cancer drugs that target folate metabolism.
Cannot be mapped to the provided FDA label excerpts for VYKOURA because the provided label-assessment meta-content states it could not determine support/contradiction/mention for the claims without an exact claim-to-label mapping; thus support status is not established using only the provided label text.
Leucovorin is also used in some settings involving folic-acid deficiency.
Label excerpt includes treatment of megaloblastic anemias due to folic acid deficiency, but the evaluation cannot be verified as a direct match to the AI claim using the supplied label-assessment process, which states claims could not be mapped.
Leucovorin is used to treat folate-related complications.
The label excerpt specifies particular indications (e.g., megaloblastic anemia due to folic acid deficiency and toxicity reduction with folate antagonists), but the broad wording 'folate-related complications' cannot be confirmed as supported vs. overly general from the provided evidence-mapping information.
“Leucovorin GSK” refers to leucovorin products marketed by GSK (GlaxoSmithKline).
No label excerpt addresses manufacturer/product naming 'Leucovorin GSK'; cannot confirm support using only provided label content.
The exact strength, formulation, and packaging of Leucovorin GSK depend on the specific product in a given country and the concentration in the package.
No provided FDA label excerpt supports country-specific packaging/manufacturer distribution statements.
Leucovorin is typically given under oncology or specialist supervision.
No provided label excerpt states administration setting/supervision; cannot confirm support.
The dosing of leucovorin depends on the chemotherapy drug being used.
The label provides dose schedules tied to specific contexts (e.g., rescue after high-dose methotrexate; reduce toxicity of folic acid antagonists/DHFR inhibitors), but the specific causal phrasing 'depends on the chemotherapy drug being used' cannot be validated through the provided mapping approach.
Leucovorin rescue timing and dose depend on the chemotherapy drug being used.
The label provides timing (e.g., begin 24 hours after starting MTX infusion) and dosing tied to methotrexate rescue; however, support cannot be confirmed under the supplied claim-to-label mapping constraints.
Leucovorin dosing depends on the treatment protocol.
While the label describes specific regimens and adjustments, the general statement 'depends on the treatment protocol' is not directly supported by the provided excerpts.
Leucovorin dosing depends on kidney function.
The label includes guidance to extend rescue in impaired elimination including renal impairment, but the claim is not precisely tied to the label wording; support status cannot be established with the supplied evidence mapping limitations.
Leucovorin dosing depends on other patient factors.
The label excerpts mention specific factors (impaired elimination/renal impairment) and monitoring, but 'other patient factors' is too nonspecific to verify as supported.
The prescription label and clinician instructions determine the leucovorin schedule.
This is not directly supported by the provided label excerpts.
Common side effects of leucovorin can include gastrointestinal symptoms such as nausea.
The provided adverse reactions section excerpt only lists hypersensitivity and hypercalcemia as clinically significant adverse reactions; GI nausea is not supported by the provided excerpts.
Common side effects of leucovorin can include general reaction-type effects.
No provided excerpt supports 'general reaction-type effects' as common adverse reactions.
More serious reactions to leucovorin are less common but can occur with any medication.
The provided adverse reactions/warnings excerpts do not support this general comparative frequency statement.
Key safety considerations with leucovorin are tied to correct use with chemotherapy and correct dosing.
Label excerpts include key safety items (hypersensitivity, hypercalcemia, administration errors like intrathecal administration); the claim is broad and not directly anchored to those label items using the provided evidence mapping.
Using the wrong form or schedule of leucovorin can change outcomes.
The label excerpt warns against administration errors (e.g., intrathecal) and emphasizes correct dosing/rate; 'wrong form or schedule' is not explicitly supported as stated.
Patients and caregivers should follow the exact protocol provided by the treating team.
Patient counseling excerpt advises patients to follow specific instructions (hypersensitivity and hypercalcemia reporting and inform healthcare providers of concomitant drugs), but the phrase 'exact protocol provided by the treating team' is not directly supported in the provided counseling excerpt.
Leucovorin is widely available in generic forms in many markets.
No provided label excerpts support statements about availability or generic market penetration.
Contradictions
Low
AI Statement
No direct contradictions can be verified from the provided evidence-mapping content.
Label Reference
N/A
Important Omissions
If evaluating VYKOURA dosing/administration: instructions about not administering intrathecally; IV/IM routes; do not exceed 160 mg/min infusion rate; monitoring serum creatinine and methotrexate at specified intervals; IV fluids and urine alkalinization targets; and specific dosing regimens for rescue vs toxicity reduction vs folic acid deficiency.
Importance:
High
FDA label contraindication: severe hypersensitivity reaction to leucovorin/folic acid/levoleucovorin (including anaphylaxis).
Importance:
High
Drug interaction specifics: glucarpidase spacing; avoidance of concomitant trimethoprim-sulfamethoxazole.
Importance:
Moderate
Warned adverse reaction specifics: hypersensitivity reactions and hypercalcemia, rather than broad/unspecified 'general reaction-type effects' or GI nausea as 'common'.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims are either not supported by the provided VYKOURA label excerpts (e.g., GI nausea as common) or too nonspecific to verify; additionally, major label-required safety and administration details (route restrictions, infusion rate limits, monitoring targets, key drug interactions) appear omitted from the claims as presented, which could contribute to misuse risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Cannot establish label support because the supplied material does not provide a verifiable claim-to-label mapping, and multiple safety/AE/administration/interaction details present in the label are missing or presented in unsupported/general terms.
Suggested Improvement
Evaluate each specific claim against exact VYKOURA label wording (Indications, Dosage & Administration, Contraindications, Warnings/Precautions, Adverse Reactions, Drug Interactions). Remove unsupported generalizations (e.g., 'common GI nausea') and include label-required administration safety points (no intrathecal; do not exceed 160 mg/min IV rate), monitoring requirements, and key interactions (glucarpidase timing; avoid TMP-SMX).